Literature DB >> 7672872

Infections due to Rhodococcus equi in three HIV-infected patients: microbiological findings and antibiotic susceptibility.

M T Mascellino1, E Iona, R Ponzo, C M Mastroianni, S Delia.   

Abstract

Infections of Rhodococcus equi, a well-known pathogen in animals which causes cavitated pneumonia similar to that caused by mycobacteria, were studied in three HIV-infected patients. This microorganism was isolated in the bronchoalveolar washings of two patients and in the sputum of the third. In two patients, Rh. equi represented the first clinical opportunistic manifestation of HIV disease. One patient died of concomitant Pneumocystis infection. The eradication of the microorganism occurred in two out of three patients. It was found that no isolates were resistant to erythromycin, claritromycin, rifampin, vancomycin, teicoplanin, imipenem, gentamycin or azithromycin (MIC values < or = 0.1 microgram/ml). Moreover, the quinolones (ciprofloxacin and ofloxacin) were found to be less effective, whereas neither the beta-lactam antibiotics nor chloramphenicol were effective therapy for this microrganism. At least two antimicrobial agents should be given contemporaneously to treat these infections for a period of up to several months. Our results suggest that the combinations erythromycin + rifampin or imipenem + teicoplanin are the most effective treatments in Rh. equi infections.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7672872

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Res        ISSN: 0251-1649


  8 in total

1.  Characterization of mutations in the rpoB gene associated with rifampin resistance in Rhodococcus equi isolated from foals.

Authors:  M Fines; S Pronost; K Maillard; S Taouji; R Leclercq
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

Review 2.  Rifampin combination therapy for nonmycobacterial infections.

Authors:  Graeme N Forrest; Kimberly Tamura
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

3.  Emergence of rifampin-resistant Rhodococcus equi with several types of mutations in the rpoB gene among AIDS patients in northern Thailand.

Authors:  Norichika Asoh; Hiroshi Watanabe; Marguerite Fines-Guyon; Kiwao Watanabe; Kazunori Oishi; Weerayut Kositsakulchai; Tippaya Sanchai; Khemrassamee Kunsuikmengrai; Sumpun Kahintapong; Banyong Khantawa; Prasit Tharavichitkul; Thira Sirisanthana; Tsuyoshi Nagatake
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

4.  The genome of a pathogenic rhodococcus: cooptive virulence underpinned by key gene acquisitions.

Authors:  Michal Letek; Patricia González; Iain Macarthur; Héctor Rodríguez; Tom C Freeman; Ana Valero-Rello; Mónica Blanco; Tom Buckley; Inna Cherevach; Ruth Fahey; Alexia Hapeshi; Jolyon Holdstock; Desmond Leadon; Jesús Navas; Alain Ocampo; Michael A Quail; Mandy Sanders; Mariela M Scortti; John F Prescott; Ursula Fogarty; Wim G Meijer; Julian Parkhill; Stephen D Bentley; José A Vázquez-Boland
Journal:  PLoS Genet       Date:  2010-09-30       Impact factor: 5.917

5.  Pangenome and Phylogenomic Analysis of the Pathogenic Actinobacterium Rhodococcus equi.

Authors:  Elisa Anastasi; Iain MacArthur; Mariela Scortti; Sonsiray Alvarez; Steeve Giguère; José A Vázquez-Boland
Journal:  Genome Biol Evol       Date:  2016-10-23       Impact factor: 3.416

6.  Clonal Confinement of a Highly Mobile Resistance Element Driven by Combination Therapy in Rhodococcus equi.

Authors:  Sonsiray Álvarez-Narváez; Steeve Giguère; Elisa Anastasi; Jack Hearn; Mariela Scortti; José A Vázquez-Boland
Journal:  mBio       Date:  2019-10-15       Impact factor: 7.867

Review 7.  The pathogenic actinobacterium Rhodococcus equi: what's in a name?

Authors:  José A Vázquez-Boland; Wim G Meijer
Journal:  Mol Microbiol       Date:  2019-06-17       Impact factor: 3.501

8.  Antimicrobial Resistance Spectrum Conferred by pRErm46 of Emerging Macrolide (Multidrug)-Resistant Rhodococcus equi.

Authors:  Erdal Erol; Mariela Scortti; Jordan Fortner; Mukesh Patel; José A Vázquez-Boland
Journal:  J Clin Microbiol       Date:  2021-07-28       Impact factor: 5.948

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.